G1 Therapeutics, Inc.
GTHXDelisted Sep 18, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001560241
G1 Therapeutics, Inc. was delisted on Sep 18, 2024; its insiders filed their last Form 4 on Sep 18, 2024; 88 institutions reported holding it in 13F filings for Q2 2024, worth $45.5M in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in G1 Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
GTHX is no longer listed, so this page shows Q2 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 88
- +2 vs. Q1 2024
- Shares held
- 19.9M
- +5.63M (+39.4%) vs. Q1 2024
- Total value
- $45.5M
- −$16.1M (−26.2%) vs. Q1 2024
- New holders
- 26
- 33 more added
- Sold out
- 24
- 17 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GTHX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 88 | $45.5M |
| Q1 2024 | 86 | $61.6M |
| Q4 2023 | 87 | $38.5M |
| Q3 2023 | 72 | $15.8M |
| Q2 2023 | 80 | $38.6M |
| Q1 2023 | 97 | $51.5M |
| Q4 2022 | 116 | $125.1M |
| Q3 2022 | 104 | $287.5M |
| Q2 2022 | 98 | $98.2M |
| Q1 2022 | 115 | $183.8M |
| Q4 2021 | 108 | $270.6M |
| Q3 2021 | 115 | $357.8M |
| Q2 2021 | 114 | $541.8M |
| Q1 2021 | 123 | $582.2M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding G1 Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −26,703−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,042−100.0% | Sold out |
| Jefferies Financial Group Inc. | 0 | $0 | 0.00% | −16,100−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −15,614−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −14,991−100.0% | Sold out |
| Oxford Asset Management LLP | 0 | $0 | 0.00% | −14,703−100.0% | Sold out |
| Financial Advocates Investment Management | 0 | $0 | 0.00% | −14,450−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −14,216−100.0% | Sold out |
| CTC Alternative Strategies, Ltd. | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −8,800−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −298−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −1,338−100.0% | Sold out |